N-(t-butyloxycarbonyl)-β-homoisoleucine | 218608-82-3

• 物质功能分类: 生物化工 - 氨基酸及其衍生物 - 异亮氨酸类衍生物
• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: N-(t-butyloxycarbonyl)-β-homoisoleucine
• 英文别名: Boc-l-β³h-isoleucine；Boc-L-β-homoisoleucine；Boc-L-beta-homoisoleucine；(3R,4S)-4-methyl-3-[(2-methylpropan-2-yl)oxycarbonylamino]hexanoic acid
• CAS: 218608-82-3
• 化学式: C₁₂H₂₃NO₄
• 分子量: 245.319
• InChiKey: CMRZYYUYDQRCEO-DTWKUNHWSA-N

物化性质

• 熔点：
  86 °C
• 沸点：
  374.3±25.0 °C(Predicted)
• 密度：
  1.046±0.06 g/cm3(Predicted)
• 溶解度：
  溶于氯仿、二氯甲烷、乙酸乙酯、DMSO、丙酮等。

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  17
• 可旋转键数：
  7
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.83
• 拓扑面积：
  75.6
• 氢给体数：
  2
• 氢受体数：
  4

安全信息

• 危险等级：
  IRRITANT
• WGK Germany：
  3
• 海关编码：
  2924199090
• 危险性防范说明：
  P280,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335

反应信息

• 作为反应物：
  描述：

  N-(t-butyloxycarbonyl)-β-homoisoleucine 在 盐酸 、 1-羟基苯并三唑 、 N,N'-二环己基碳二亚胺 作用下， 以 四氢呋喃 、 1,4-二氧六环 为溶剂， 生成
  参考文献：
  名称：

  Antiplasmodial activity of new 4-aminoquinoline derivatives against chloroquine resistant strain

  摘要：

  Emergence and spread of multidrug resistant strains of Plasmodium falciparum has severely limited the antimalarial chemotherapeutic options. In order to overcome the obstacle, a set of new side-chain modified 4-aminoquinolines were synthesized and screened against chloroquine-sensitive (3D7) and chloroquine-resistant (K1) strains of P. falciparum. The key feature of the designed molecules is the use of methylpiperazine linked α, β(3)- and γ-amino acids to generate novel side chain modified 4-aminoquinoline analogues. Among the evaluated compounds, 20c and 30 were found more potent than CQ against K1 and displayed a four-fold and a three-fold higher activity respectively, with a good selectivity index (SI=5846 and 11,350). All synthesized compounds had resistance index between 1.06 and >14.13 as against 47.2 for chloroquine. Biophysical studies suggested that this series of compounds act on heme polymerization target.

  DOI：

  10.1016/j.bmc.2014.05.024
• 作为产物：
  描述：

  L-异亮氨酸 在 N-甲基吗啉 、 silver benzoate 、 sodium hydroxide 、 氯甲酸异丁酯 作用下， 以 1,4-二氧六环 、 乙醚 、 水 为溶剂， 生成 N-(t-butyloxycarbonyl)-β-homoisoleucine
  参考文献：
  名称：

  Antiplasmodial activity of new 4-aminoquinoline derivatives against chloroquine resistant strain

  摘要：

  Emergence and spread of multidrug resistant strains of Plasmodium falciparum has severely limited the antimalarial chemotherapeutic options. In order to overcome the obstacle, a set of new side-chain modified 4-aminoquinolines were synthesized and screened against chloroquine-sensitive (3D7) and chloroquine-resistant (K1) strains of P. falciparum. The key feature of the designed molecules is the use of methylpiperazine linked α, β(3)- and γ-amino acids to generate novel side chain modified 4-aminoquinoline analogues. Among the evaluated compounds, 20c and 30 were found more potent than CQ against K1 and displayed a four-fold and a three-fold higher activity respectively, with a good selectivity index (SI=5846 and 11,350). All synthesized compounds had resistance index between 1.06 and >14.13 as against 47.2 for chloroquine. Biophysical studies suggested that this series of compounds act on heme polymerization target.

  DOI：

  10.1016/j.bmc.2014.05.024

文献信息

• Homologation of α-amino acids to β-amino acids using Boc₂O
  作者：Ganga-Ramu Vasanthakumar、Basanagoud S. Patil、Vommina V. Suresh Babu

  DOI：10.1039/b204652k

  日期：——

  The use of Boc2O as a coupling agent in the homologation of N-urethane protected-α-amino acid to its β-homomers by the Arndt–Eistert method is described. The homologation gives good yields without racemization. The use of Boc2O as a coupling agent not only allows the easy scale up of the process but also it is cost effective.

  在利用Arndt-Eistert方法将N-羟基脲保护的α-氨基酸同系化为其β-同系物的过程中，使用Boc2O作为偶联剂的方法已被描述。该同系化反应能够获得良好的产率，且不会发生消旋化。使用Boc2O作为偶联剂不仅使得过程易于放大，而且在成本方面也是经济有效的。
• Synthesis of angiotensin II analogs by incorporating .beta.-homotyrosine or .beta.-homoisoleucine residues
  作者：K. Stachowiak、M. C. Khosla、K. Plucinska、P. A. Khairallah、F. M. Bumpus

  DOI：10.1021/jm00195a025

  日期：1979.9

  [1-Sarcosine,4-beta-homotyrosine]-(I), [5-beta-homoisoleucine]-(II), and [1-sarcosine,5-beta-homoisoleucine]angiotensin II (III) were synthesized by Merrifield's solid-phase procedure to study the effect of pressor activity and duration of action. The analogues I--III possessed, respectively, 1.98, 2.82, and 29.2% pressor activity of angiotensin II (vagotomized, ganglion-blocked rats by single-injection procedure)

  通过Merrifield's固体合成[1-Sarcosine，4-β-高酪氨酸]-（I），[5-β-高苏氨酸]-（II）和[1-肌氨酸，5-β-高苏氨酸]血管紧张素II（III）。分阶段的程序，以研究升压活动和作用持续时间的影响。类似物I-III分别具有1.98、2.82和29.2％的血管紧张素II（通过单次注射程序迷走神经节，阻断神经节的大鼠）的升压活性，作用持续时间分别为5.5、6.7和4.7分钟。等压剂量的血管紧张素II的相对作用持续时间分别为5.2、6.3和5.3分钟。当与亮氨酸氨基肽酶一起孵育时，II的降解速度与血管紧张素II一样快。当位置1替换为肌氨酸时，这种降解变得相当缓慢。将所有这些类似物与胰凝乳蛋白酶一起温育，直至3 h都几乎没有降解或没有降解。结果表明，在血管紧张素II的4或5位增加一个碳原子的链长增加了对胰凝乳蛋白酶降解的抗性，而在体内的作用持续时间没有任何增加。此外，所有类似物均显示出低升压活性。
• Compounds That Inhibit Replication Of Human Immunodeficiency Virus
  申请人：Balzarini Maria Rene Jan

  公开号：US20080076824A1

  公开（公告）日：2008-03-27

  The present invention relates to the discovery of a novel class of compounds that inhibit the replication of human immunodeficiency virus (HIV) and approaches to identify these compounds. More specifically, it has been found that enzymatically prepared alpha-hydroxyglycinamide and synthetically prepared alpha-hydroxyglycinamide inhibit the replication of HIV in human serum. Embodiments include methods to identify modified glycinamide compounds that inhibit HUV, methods to isolate and synthesize modified glycinamide compounds, and therapeutic compositions comprising these compounds.

  本发明涉及一种新型化合物类别的发现，该类化合物能够抑制人类免疫缺陷病毒（HIV）的复制，并提供了鉴定这些化合物的方法。具体来说，发现经酶法制备的α-羟基甘氨酰胺和人工合成的α-羟基甘氨酰胺能够抑制HIV在人血清中的复制。实施例包括鉴定抑制HUV的改性甘氨酰胺化合物的方法，分离和合成改性甘氨酰胺化合物的方法，以及包含这些化合物的治疗组合物。
• Protein–Protein Interface Mimicry by an Oxazoline Piperidine-2,4-dione
  作者：Xun Li、Jaru Taechalertpaisarn、Dongyue Xin、Kevin Burgess

  DOI：10.1021/ol5036547

  日期：2015.2.6

  Representative minimalist mimics 1 were prepared from amino acids. Scaffold 1 was not designed to mimic any particular secondary structure, but simulated accessible conformations of this material were compared with common ideal secondary structures and with >125,000 different protein-protein interaction (PPI) interfaces. This data mining exercise indicates that scaffolds 1 can mimic features of sheet-turn-sheets, somewhat fewer helical motifs, and numerous PPI interface regions that do not resemble any particular secondary structure.
• Kantharaju; Suresh Babu, Vommina V., Indian Journal of Chemistry - Section B Organic and Medicinal Chemistry, 2004, vol. 43, # 10, p. 2152 - 2158
  作者：Kantharaju、Suresh Babu, Vommina V.

  DOI：——

  日期：——